Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?
A clinical case shows how medical commercialism poses risks to patients without symptoms who get full body scans. Screening for pre-morbid disease detection is valuable if implemented correctly but calls for physician caution.